Structure and function in the p53 family

Cell Death and Differentiation

Volumn 6, Issue 12, 1999, Pages 1169-1173

  Arrowsmith, C H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Oligomerization; Protein protein interaction; SAM domain; Tumor suppressor

Indexed keywords

DNA BINDING PROTEIN; PROTEIN P53; PROTEIN P63; PROTEIN P73; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; CARBOXY TERMINAL SEQUENCE; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; REVIEW; STRUCTURE ACTIVITY RELATION; TUMOR SUPPRESSOR GENE;

EID: 0033387525     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4400619     Document Type: Review

References (43)

1. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R and Harris CC (1996) Database of p53 gene somatic mutations in human tumors and cell lines. Nucl. Acids Res. 24: 141-146
2. Hollstein M, Sidransky D, Vogelstein B and Harris CC (1991) p53 mutations in human cancer. Science 253: 49-53
3. Ko LJ and Prives C (1996) p53: puzzle and paradigm. Genes Dev. 10: 1054-1072
4. Levine AJ (1997) p53, the Cellular Gatekeeper for Growth and Division. Cell 88: 323-331
5. Donehower LA and Bradley A (1993) The tumor suppressor p53. Biochimica et Biophysica Acta 1155: 181-205
6. Lane DP (1992) p53, guardian of the genome. Nature 358: 15-16
7. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC and Vogelstein B (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708
8. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan J-C, Valent A, Minty A, Chalon P, Lelias J-M, Dumont X, Ferrera P, McKeon F and Caput D (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other cancers. Cell 809-819
9. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D and McKeon F (1998) p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2: 305-316
10. Schmale H and Bamberger C (1997) A novel protein with strong homology to the tumor suppressor p53. Oncogene 15: 1363-1367
11. Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I, Ikawa Y, Nimura Y, Nakagawara A, Obinata M and Ikawa S (1998) Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nature Medicine 4: 839-843
12. Trink B, Okami K, Wu L, Sriuranpong V, Jen J and Sidransky D (1998) A new human p53 homologue. Nature Medicine 4: 747-748
13. De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M, Levrero M and Melino G (1998) Two new p73 splice variants, gamma and delta, with different transcriptional activity. J. Exp. Med. 188: 1763-1768
14. De Laurenzi V, Catani M, Costanzo A, Terrinoni A, Corazzari M, Levrero M, Knight R and Melino G (1999) Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta. Cell Death Differ. 6: 389-390
15. Kussie PH, Gorina S, Marechal B, Elenbaas B, Moreau J, Levine AJ and Pavletich NP (1996) Crystal structure of the MDM2 oncoprotein bound to the transactivation domain of the p53 tumor suppressor. Science 274: 948-953
16. Balint E, Bates S and Vousden KH (1999) Mdm2 binds to p73 without targeting degradation. Oncogene 18: 3923-3929
17. Cho Y, Gorina S, Jeffery P and Pavletich N (1994) Crystal structure of p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-355
18. Davison TD, Vagner C, Kaghad M, Ayed A, Caput D and Arrowsmith CH (1999) p73 and p63 are homo-tetramers capable of weak hetero-typic interactions with each other but not p53. J. Biol. Chem. 274: 18709-18714
19. Sharkey M, Graba Y and Scott MP (1997) Hox genes in evolution: protein surfaces and paralog groups. Trends In Genetics 13: 145-155
20. Schreiber-Agus N, Alland L, Muhle R, Goltz J, Chen K, Stevens L, Stein D and DePinho RA (1997) A biochemical and biological analysis of Myc superfamily interactions. Curr. Topics in Microbiol. & Immun. 224: 159-168
21. Mateu MG and Fersht AR (1999) Mutually compensatory mutations during evolution of the tetramerization domain of tumor suppressor p53 lead to impaired hetero-oligomerization. Proc. Natl. Acad. Sci. USA 96: 3595-3599
22. Di Como CJ, Gaiddon C and Prives C (1999) p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol. 19: 1438-1449
23. Zhu J, Jiang J, Zhou W and Chen X (1998) The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res. 58: 5061-5065
24. Chi S-W, Ayed A and Arrowsmith CH (1999) Solution structure of a conserved C-terminal domain of p73 with structural homology to the SAM domain. EMBO J. 18: 4438-4445
25. Stapleton D, Balan I, Pawson T and Sicheri F (1999) The crystal structure of an Eph receptor SAM domain reveals a mechanism for modular dimerization. Nat. Struct. Biol. 6: 44-49
26. Thanos CD, Goodwill KE and Bowie JU (1999) Oligomeric structure of the human EphB2 receptor SAM domain. Science 283: 833-836
27. Smalla M, Schmieder P, Kelly M, terLaak A, Krause G, Ball L, Wahl M, Bork P and Oschkinat H (1999) Solution structure of the receptor tyrosine kinase EphB2 SAM domain and identification of two distinct homotypic interaction sites. Protein Sci. 10: 1954-1961
28. Schultz J, Ponting CP, Hofmann K and Bork P (1997) SAM as a protein interaction domain involved in developmental regulation. Protein Sci. 6: 249-253
29. Bork P and Koonin EV (1998) Predicting functions from protein sequences where are the bottlenecks? Nat. Genet. 18: 313-318
30. Thanos CD and Bowie JU (1999) p53 Family members p63 and p73 are SAM domain-containing proteins. Protein Sci. 8: 1708-1710
31. Jousset C, Carron C, Boureux A, Quang CT, Oury C, Dusanter-Fourt I, Charon M, Levin J, Bernard O and Ghysdael J (1997) A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein. EMBO J. 16: 69-82
32. Golub TR, Barker GF, Lovett M and Gilliland DG (1994) Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5; 12) chromosomal translocation. Cell 77: 307-316
33. Golub TR (1997) TEL gene rearrangements in myeloid malignancy. Hematol. Oncol. Clin. North. Am. 11: 1207-1220
34. Peterson AJ, Kyba M, Bornemann D, Morgan K, Brock HW and Simon J (1997) A domain shared by the Polycomb group proteins Scm and ph mediates heterotypic and homotypic interactions. Mol. Cell. Biol. 17: 6683-6692
35. Kyba M and Brock HW (1998) The SAM domain of polyhomeotic, RAE28, and scm mediates specific interactions through conserved residues. Dev. Genet. 22: 74-84
36. Hupp TR, Meek DW, Midgley CA and Lane DP (1992) Regulation of the specific DNA binding function of p53. Cell 71: 875-886
37. Almog N and Rotter V (1998) An insight into the life of p53: a protein coping with many functions! Review of the 9th p53 Workshop, Crete, May 9-13, 1998. Biochim. Biophys. Acta 1378: R43-54
38. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR and Bradley A (1999) p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398: 708-713
39. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C and McKeon F (1999) p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398: 714-718
40. Lee W, Harvey TS, Yin Y, Yau P, Litchfield D and Arrowsmith CH (1994) Solution structure of the tetrameric minimum transforming domain of p53. Nat. Struct. Biol. 1: 877-890
41. Kraulis PJ (1991) MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24: 946-950
42. Ishioka C, Shimodaira H, Englert C, Shimada A, Osada M, Jia J-Q, Suzuki T, Gamo M and Kanamaru R (1997) Oligomerization is not essential for growth suppression by p53 in p53-deficient Osteosarcoma Saos-2 cells. Biochem. Biophys. Res. Com. 232: 54-60
43. Zeng X, Chen L, Jost CA, Maya R, Keller D, Wang X, Kaelin Jr WG, Oren M, Chen J and Lu H (1999) MDM2 suppresses p73 function without promoting p73 degradation. Mol. Cell. Biol. 19: 3257-3266